Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Digital Mammography, Ultrasound, MRI, and PET Scans in Women With Newly Diagnosed Breast Cancer

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified January 2007 by Abramson Cancer Center of the University of Pennsylvania.
Recruitment status was:  Active, not recruiting
National Cancer Institute (NCI)
Information provided by:
Abramson Cancer Center of the University of Pennsylvania Identifier:
First received: September 13, 2005
Last updated: January 24, 2017
Last verified: January 2007

RATIONALE: Diagnostic procedures, such as digital mammography, ultrasound, MRI, and PET scans, may help find breast cancer and find out how far the disease has spread.

PURPOSE: This phase II/III trial is studying digital mammography, ultrasound, MRI, and PET scans to compare how well they find the extent and spread of breast cancer in women with newly diagnosed breast cancer.

Condition Intervention Phase
Breast Cancer
Procedure: breast imaging study
Procedure: comparison of screening methods
Procedure: magnetic resonance imaging
Procedure: positron emission tomography
Procedure: radiomammography
Procedure: ultrasound imaging
Radiation: fludeoxyglucose F 18
Phase 2
Phase 3

Study Type: Interventional
Study Design: Masking: No masking
Primary Purpose: Diagnostic
Official Title: Evaluation of Multimodality Breast Imaging: Project 3-Lesion Staging

Resource links provided by NLM:

Further study details as provided by Abramson Cancer Center of the University of Pennsylvania:

Primary Outcome Measures:
  • Size of the index lesion (3 dimensions and tumor volume)
  • Relative sensitivity/specificity of imaging in identifying additional cancer foci at least 2 cm from the index lesion margin
  • Relative yield of imaging in detecting lymph node and distant metastases

Secondary Outcome Measures:
  • Positive predictive value of imaging-identified suspicious incidental lesions
  • Negative predictive value of imaging (compared to mastectomy sectioning) for identifying unifocal disease
  • Imaging features predictive of lymph node status

Estimated Enrollment: 400
Study Start Date: October 1999
Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)
Detailed Description:


  • Compare the ability of digital mammography, ultrasound, MRI, and fludeoxyglucose F 18 positron emission tomography (FDG-PET) in depicting the extent of the index lesion within an affected breast in women with newly diagnosed breast cancer.
  • Compare the ability of digital mammography, ultrasound, MRI, and FDG-PET in identifying additional foci of cancer in the affected breast.
  • Estimate the accuracy of FDG-PET in predicting the status of the axillary lymph nodes, using sentinel node sampling as the gold standard.
  • Determine whether diffuse or multifocal cancers detected on MRI, ultrasound, digital mammography, and FDG-PET can be predicted based on mammographic, clinical, or pathologic findings.
  • Based on correlation of various imaging techniques and clinical and pathological findings, generate a profile of patients at risk for mammographically and clinically occult, diffuse or multifocal disease.
  • Collect pilot data on the accuracy of digital tomosynthesis in determining the extent of breast cancer (in women consenting to the contrast-enhanced tomosynthesis study).

OUTLINE: This is a prospective study. Patients are stratified according to breast density (fatty vs scattered/less than 50% dense vs heterogeneously dense/greater than 50% dense vs extremely dense), presentation (palpable abnormalities vs imaging abnormalities only), and image findings (density vs calcification).

Patients undergo MRI, ultrasound, digital mammography, and fludeoxyglucose F 18 positron emission tomography. Results of imaging are compared by a panel of physicians to determine efficacy of each method. Consenting patients also undergo digital tomosynthesis with or without contrast enhancement.

PROJECTED ACCRUAL: A total of 400 patients will be accrued for this study.


Ages Eligible for Study:   18 Years to 120 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No


  • Confirmed diagnosis of breast cancer by biopsy

    • Malignant fine-needle aspiration, core needle, mammotome, or excisional biopsy
  • Newly diagnosed disease

    • Has undergone a film screening mammogram within the past 90 days
  • Planning to undergo definitive surgery at the Hospital of the University of Pennsylvania
  • No cancer in the ipsilateral breast within the past 5 years
  • Hormone receptor status not specified


  • Female
  • Menopausal status not specified
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • Blood glucose ≤ 200 mg/dL
  • No contraindications to MRI including, but not limited to, any of the following:

    • Pacemaker
    • Magnetic aneurysm clip or other surgically implanted magnetic device
    • Severe claustrophobia
  • No prior allergic reaction to iodinated contrast agents or a history of severe allergic reactions to other drugs or foods (for patients consenting to the contrast-enhanced tomosynthesis study)


  • See Disease Characteristics
  • No preoperative adjuvant therapy for known locally advanced cancer
  • Concurrent participation in other breast cancer studies allowed for conditions in the contralateral breast

    • Participation in a prevention study for a high-risk population (for patients with negative or benign findings in the contralateral breast) allowed
    • Participation in another diagnostic study (for patients with abnormal imaging findings of the contralateral breast and are recommended for biopsy) allowed
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00194337

United States, Pennsylvania
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Sponsors and Collaborators
Abramson Cancer Center of the University of Pennsylvania
National Cancer Institute (NCI)
Principal Investigator: Abass Alavi, MD Abramson Cancer Center of the University of Pennsylvania
  More Information Identifier: NCT00194337     History of Changes
Other Study ID Numbers: CDR0000515329
Study First Received: September 13, 2005
Last Updated: January 24, 2017

Keywords provided by Abramson Cancer Center of the University of Pennsylvania:
stage I breast cancer
stage II breast cancer
stage IIIA breast cancer
stage IIIB breast cancer
stage IIIC breast cancer
stage IV breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Fluorodeoxyglucose F18
Molecular Mechanisms of Pharmacological Action processed this record on May 25, 2017